Who is sponsoring NCT06227624?

NCT06227624 is sponsored by National Liver Institute, Egypt.

What drugs are being tested in NCT06227624?

Interventions in NCT06227624: Oral zinc sulfate and standard phototherapy.

What condition does NCT06227624 study?

NCT06227624 studies Neonatal Jaundice.

Is NCT06227624 still recruiting?

NCT06227624 is currently completed. Last updated 29 January 2024.

Last reviewed 2024-01-29 · How we verify

NCT06227624

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia

Completed Phase 3 Last updated 29 January 2024

What this trial tests

Phase 3 trial testing Oral zinc sulfate and standard phototherapy in Neonatal Jaundice in 192 participants. Completed in 1 January 2020.

Timeline

1 June 2018

Primary endpoint
1 June 2019

1 January 2020

Quick facts

Lead sponsor	National Liver Institute, Egypt
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	192
Start date	1 June 2018
Primary completion	1 June 2019
Estimated completion	1 January 2020
Sites	1 location across Egypt

Drugs / interventions tested

Oral zinc sulfate and standard phototherapy — full drug profile →

Conditions studied

Neonatal Jaundice — all drugs for Neonatal Jaundice →

Sponsor

National Liver Institute, Egypt

Who can join

Adults 1 Hour to 28 Days, any sex, with Neonatal Jaundice. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to determine the role of oral zinc in reducing the neonatal indirect hyperbilirubinemia if used concomitant with the standard phototherapy

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Neonatal Jaundice

Currently open trials in the same condition.

NCT06963450 — NeoSCB App for Screening Jaundice in Newborns · recruiting
NCT06399146 — Evaluation of Bilirubin Estimates in Newborns From Smartphone Digital Images in a Population in Botswana · NA · recruiting
NCT05521607 — Evaluation of a Smartphone-based Screening Tool (Picterus JP) for Neonatal Jaundice (Chicago) · NA · recruiting

Other National Liver Institute, Egypt trials

Trials by the same sponsor.

NCT07331142 — CBD Stenting vs Non-Stenting for Choledocholithiasis · NA · completed
NCT06948279 — Immediate vs. Elective Endoscopic Removal of Large CBD Stones in High-Risk Elderly Patients · NA · completed
NCT07337291 — Double Stent for Biliary Stones in Cirrhotic Patients · NA · completed
NCT05184491 — Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management · Phase 4 · unknown
NCT06384443 — Proton Pump Inhibitors in Cirrhotic Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06227624 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Liver Institute, Egypt
Last refreshed: 29 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06227624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing